This document summarizes a proposed nanoparticle system to remove amyloid-β aggregates in vitro for the treatment of Alzheimer's disease. The system uses multifunctional iron-oxide nanoparticles coated with dextran and biotinylated anti-amyloid-β antibodies. The nanoparticles are designed to cross the blood-brain barrier via activation of adenosine receptors on brain endothelial cells, then target and remove amyloid-β aggregates using an applied magnetic field. The document outlines the synthesis, characterization, and testing of the nanoparticles, including in vitro studies on cell lines and brain tissue, as well as potential issues to address such as blood-brain barrier permeability, dose optimization, and toxicity evaluation.